FDA approves Bristol-Myers combo therapy for lung cancer
The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Lung Cancer | Merck